市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Annovis Bio, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
-0.1
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.13 |
|
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 14.69% |
| 机构持股比例 | 16.09% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Lokken Investment Group Llc | 31 Mar 2025 | 29,235 |
| 52周波幅 | ||
| 中 | 12.00 (341.18%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 Jun 2025 | 12.00 (341.18%) | 购买 | 3.06 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 12 Aug 2025 | 公告 | Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results |
| 07 Aug 2025 | 公告 | Annovis Completes Full Patent Transfer to Crystal Buntanetap |
| 26 Jun 2025 | 公告 | Annovis to Attend the AAIC 2025 with Four Poster Presentations |
| 19 Jun 2025 | 公告 | Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance |
| 05 Jun 2025 | 公告 | Annovis to Host Webinar and Live Q&A on June 24, 2025 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合